Limits...
A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC.

Michael M, Wirth A, Ball DL, MacManus M, Rischin D, Mileshkin L, Solomon B, McKendrick J, Milner AD - Br. J. Cancer (2005)

Bottom Line: The overall radiological response rate was 65% (n=23: complete response 4% and partial response 61%) and infield FDG-PET responses were seen in 89% (n=18).There was an improvement or stabilisation of symptoms and quality of life.This regimen was tolerable and produced meaningful responses for patients for whom locoregional control is required, but who are unsuitable for radical CRT.

View Article: PubMed Central - PubMed

Affiliation: The Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, Victoria 8006, Australia. michael.michael@petermac.org

ABSTRACT
The role of concurrent chemoradiotherapy (CRT) in patients with non-small-cell lung cancer (NSCLC) unsuitable for radical therapy but who require locoregional treatment has not been defined. The aims of this phase I trial were thus to develop a novel regimen of weekly chemotherapy concurrent with high-dose palliative RT (40 Gy/20 fractions) and assess its tolerability, objective and symptomatic response rates. Eligible patients had stage I-IIIB NSCLC unsuitable for radical RT or limited stage IV disease, ECOG PS

Show MeSH

Related in: MedlinePlus

Change in LCSS scores between baseline and 3 weeks after CRT. (Improved: >10 mm better score after CRT. Declined: >10 mm worse score 3 weeks after CRT.)
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2361626&req=5

fig3: Change in LCSS scores between baseline and 3 weeks after CRT. (Improved: >10 mm better score after CRT. Declined: >10 mm worse score 3 weeks after CRT.)

Mentions: As shown in Figure 3, the post-CRT LCSS evaluation found that 30–50% of patients had an improvement in loss of appetite, cough and dyspnoea, with 37% of patients showing an improvement in overall symptom distress. A decline in scores was observed in up to 32% of patients subject to the parameters; for example, no patient had a decline or worsening of haemoptysis, but for 32% there was a deteriorating normal activity. A stabilisation of LCSS scores post-CRT was observed in 39–90% of patients, subject to the parameter.


A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC.

Michael M, Wirth A, Ball DL, MacManus M, Rischin D, Mileshkin L, Solomon B, McKendrick J, Milner AD - Br. J. Cancer (2005)

Change in LCSS scores between baseline and 3 weeks after CRT. (Improved: >10 mm better score after CRT. Declined: >10 mm worse score 3 weeks after CRT.)
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2361626&req=5

fig3: Change in LCSS scores between baseline and 3 weeks after CRT. (Improved: >10 mm better score after CRT. Declined: >10 mm worse score 3 weeks after CRT.)
Mentions: As shown in Figure 3, the post-CRT LCSS evaluation found that 30–50% of patients had an improvement in loss of appetite, cough and dyspnoea, with 37% of patients showing an improvement in overall symptom distress. A decline in scores was observed in up to 32% of patients subject to the parameters; for example, no patient had a decline or worsening of haemoptysis, but for 32% there was a deteriorating normal activity. A stabilisation of LCSS scores post-CRT was observed in 39–90% of patients, subject to the parameter.

Bottom Line: The overall radiological response rate was 65% (n=23: complete response 4% and partial response 61%) and infield FDG-PET responses were seen in 89% (n=18).There was an improvement or stabilisation of symptoms and quality of life.This regimen was tolerable and produced meaningful responses for patients for whom locoregional control is required, but who are unsuitable for radical CRT.

View Article: PubMed Central - PubMed

Affiliation: The Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, Victoria 8006, Australia. michael.michael@petermac.org

ABSTRACT
The role of concurrent chemoradiotherapy (CRT) in patients with non-small-cell lung cancer (NSCLC) unsuitable for radical therapy but who require locoregional treatment has not been defined. The aims of this phase I trial were thus to develop a novel regimen of weekly chemotherapy concurrent with high-dose palliative RT (40 Gy/20 fractions) and assess its tolerability, objective and symptomatic response rates. Eligible patients had stage I-IIIB NSCLC unsuitable for radical RT or limited stage IV disease, ECOG PS

Show MeSH
Related in: MedlinePlus